Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 19/20 | 0.82 |
| ▸ | PTK2 | Q05397 | 19/20 | 0.82 |
| ▸ | JAK2 | O60674 | 19/20 | 0.82 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.82 |
| ▸ | JAK1 | P23458 | 2/20 | 0.82 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2634247 | 0.90 | PTK2 (1.00) | JAK3PTK2JAK2CYP3A4JAK1 | |
| SCHEMBL2634609 | 0.89 | JAK3 (1.00) | JAK3PTK2JAK2CYP3A4JAK1 | |
| SCHEMBL12973838 | 0.88 | JAK3 (0.82) | JAK3PTK2JAK2CYP3A4JAK1 | |
| SCHEMBL2634454 | 0.88 | PTK2 (1.00) | JAK3PTK2JAK2CYP3A4JAK1 | |
| SCHEMBL2634816 | 0.87 | JAK3 (1.00) | JAK3PTK2JAK2CYP3A4JAK1 | |
| SCHEMBL2634831 | 0.86 | PTK2 (1.00) | JAK3PTK2JAK2CYP3A4JAK1 | |
| SCHEMBL12973847 | 0.85 | JAK2 (0.81) | JAK3PTK2JAK2CYP3A4JAK1 | |
| SCHEMBL2635161 | 0.82 | JAK2 (0.81) | JAK3PTK2JAK2CYP3A4JAK1 | |
| SCHEMBL2634691 | 0.81 | JAK3 (1.00) | JAK3PTK2JAK2CYP3A4JAK1 | |
| SCHEMBL2634566 | 0.81 | JAK3 (1.00) | JAK3PTK2JAK2CYP3A4JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8501936-B2 | Preparation and uses of 1,2,4-triazolo [1,5a] pyridine derivatives | CEPHALON, INC. (US) | 2013-08-06 | — | — | US | claimed |
| US-20100311693-A1 | Preparation and Uses of 1,2,4-Triazolo [1,5a] Pyridine Derivatives | CEPHALON, INC. (US) | 2010-12-09 | — | — | US | claimed |
| US-8633173-B2 | Preparation and uses of 1,2,4-triazolo [1,5a] pyridine derivatives | CEPHALON, INC (US) | 2014-01-21 | — | — | US | disclosed |
| WO-2010141796-A2 | PREPARATION AND USES OF 1,2,4-TRIAZOLO [1,5a] PYRIDINE DERIVATIVES | CEPHALON, INC. (US) | 2010-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311693-A1 | Preparation and Uses of 1,2,4-Triazolo [1,5a] Pyridine Derivatives | CCNA1, CCNY, RB1 | JAK3 175/4885PTK2 1114/4885JAK2 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.